Wedbush analyst Martin Fan initiates coverage on Nektar Therapeutics (NASDAQ: NKTR) with a Neutral rating and a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments New Coverage